150 completed, 71 terminated, 46 recruiting, 38 active not recruiting. 353 Phase 2, 89 Phase 1, 3 Phase 3.
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-11-06 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-15 | 2026-11-10 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-09-16 | 2026-11-09 |
| Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2026-09-01 | 2026-08-05 |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Emavusertib, Zanubrutinib - Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | Curis, Inc. | 108 | 2026-04-23 | 2026-06-12 |
| Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2026-01-07 | 2026-03-13 |
| Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL Venetoclax, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Zulfa Omer | 62 | 2025-12-05 | 2026-01-06 |
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | VA Office of Research and Development | 100 | 2025-10-01 | 2026-10-30 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Pirtobrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL) | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2025-07-15 | 2026-11-03 |
| A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Pirtobrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Withdrawn | AstraZeneca | 2025-06-30 | 2025-06-05 |
Showing 20 of 353. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (353) · Leukemia (65) · Lymphoma, Non-Hodgkin (64) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (52) · Leukemia, Myeloid, Acute (47) · Lymphoma, Mantle-Cell (42) · Myelodysplastic Syndromes (42) · Hodgkin Disease (37) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (37) · Lymphoma (37) · Multiple Myeloma (33) · Lymphoma, Large B-Cell, Diffuse (32) · Lymphoma, Follicular (30) · Recurrence (23) · Lymphoma, B-Cell, Marginal Zone (21)
Chronic Disease (353) · Disease Attributes (353) · Hemic and Lymphatic Diseases (353) · Pathologic Processes (353) · Pathological Conditions, Signs and Symptoms (353) · Lymphatic Diseases (350) · Neoplasms by Histologic Type (350) · Immune System Diseases (349) · Immunoproliferative Disorders (349) · Lymphoproliferative Disorders (348) · Leukemia, B-Cell (347) · Leukemia, Lymphoid (345) · Hematologic Diseases (344) · Neoplasms (333) · Leukemia (288)
Rituximab (57) · Cyclophosphamide (51) · fludarabine (44) · fludarabine phosphate (44) · venetoclax (40) · ibrutinib (32) · obinutuzumab (31) · Lenalidomide (28) · Mycophenolic Acid (28) · Whole-Body Irradiation (23) · acalabrutinib (23) · Tacrolimus (19) · ofatumumab (19) · Bendamustine Hydrochloride (18) · zanubrutinib (16)
M.D. Anderson Cancer Center (41) · Fred Hutchinson Cancer Center (11) · City of Hope Medical Center (10) · German CLL Study Group (10) · Gilead Sciences (8) · National Heart, Lung, and Blood Institute (NHLBI) (8) · Masonic Cancer Center, University of Minnesota (7) · TG Therapeutics, Inc. (7) · Massachusetts General Hospital (6) · National Cancer Institute (NCI) (6) · Dana-Farber Cancer Institute (5) · Genentech, Inc. (5) · University of California, San Diego (5) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · H. Lee Moffitt Cancer Center and Research Institute (4)
United States (263) · Italy (30) · Germany (27) · France (23) · United Kingdom (22) · China (18) · Canada (17) · Poland (17) · Australia (16) · Spain (16) · Belgium (11) · Austria (10) · Czechia (8) · Israel (8) · Brazil (7)
Alessandra Ferrajoli, MD (6) · Kerry A Rogers, MD (4) · Alessandra Ferrajoli (3) · Alessandra Ferrajoli, M.D. (3) · Januario Castro, M.D. (3) · Jennifer Brown, MD, PhD (3) · Kerry Rogers, MD (3) · Neal Flomenberg, MD (3) · Nitin Jain (3)
PMID 34398557, PMID 29358183, PMID 32499241, PMID 23065508, PMID 23524640, PMID 27601462, PMID 31023700, PMID 31208944, PMID 34608724, PMID 10204198, PMID 15911237, PMID 16186597, PMID 18003886, PMID 18039954, PMID 18334676, PMID 18418404, PMID 18997171, PMID 19225537, PMID 19706886, PMID 19843887, PMID 20307284, PMID 20408846, PMID 20595516, PMID 20940416, PMID 21725050, PMID 21844497, PMID 22133778, PMID 22184378, PMID 22331940, PMID 22490331, PMID 22571691, PMID 22869884, PMID 23265768, PMID 23270003, PMID 23435461, PMID 23716541, PMID 23801633, PMID 24431228, PMID 24443277, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24705492, PMID 24925211, PMID 25043749, PMID 25130401, PMID 25196783, PMID 25645263, PMID 25696919, PMID 26009261
P30CA015704 (8), P30CA033572 (6), 2016 (4), P30CA016672 (4), 2015 (3), 2025 (3), P01CA018029 (3), 2005 (2), 2009 (2), 2014 (2), 2018 (2), N01CM00070 (2), N01CM62207 (2), P01CA078902 (2), P30CA015083 (2)